tremelimumab
Showing 1 - 25 of 105
Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)
Not yet recruiting
- Borderline Resectable Carcinoma
- Biliary Tract Cancer
- Durvalumab
- +4 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- +2 more
- Durvalumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 18, 2023
NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +5 more
- (no location specified)
Aug 17, 2023
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC) Trial in Philadelphia (Radiotherapy, MEDI4736, Tremelimumab)
Active, not recruiting
- Metastatic
- +4 more
- Radiotherapy
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jan 6, 2023
Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)
Not yet recruiting
- Hepatocellular Carcinoma
- Durvalumab
- Tremelimumab
- (no location specified)
Sep 27, 2022
Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,
Recruiting
- Hepatocellular Cancer
- +2 more
- durvalumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)
Not yet recruiting
- Pancreatic Cancer
- +3 more
- Durvalumab
- +5 more
-
Edmonton, Alberta, CanadaCross Cancer Institute
Feb 1, 2023
Metastatic Breast Cancer Trial in New York (Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed
Completed
- Metastatic Breast Cancer
- Brain radiotherapy or Stereotactic Radiosurgery
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Aug 2, 2022
Unresectable Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)
Available
- Unresectable Hepatocellular Carcinoma
- Durvalumab
- Tremelimumab
- (no location specified)
Aug 12, 2022
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,
Terminated
- Recurrent Gynecological Cancer
- +10 more
- Durvalumab
- +2 more
-
Boston, MassachusettsMartin King
Oct 4, 2022
Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)
Recruiting
- Gastric Cancer
- Microsatellite Instability
- Durvalumab
- Tremelimumab
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022
Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)
Completed
- Endometrial Cancer
- +4 more
- Durvalumab
- Tremelimumab
-
Basking Ridge, New Jersey
- +6 more
Jan 3, 2023
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston
Recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +3 more
- Durvalumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2022
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +5 more
- Durvalumab
- +3 more
-
Buffalo, New York
- +1 more
Jan 20, 2023
Urothelial Carcinoma Trial in Amsterdam (Tremelimumab, Durvalumab, Paclitaxel)
Active, not recruiting
- Urothelial Carcinoma
- Tremelimumab
- +2 more
-
Amsterdam, NetherlandsAntoni van Leeuwenhoek Ziekenhuis
Jul 7, 2022
Nonsmall Cell Lung Cancer Trial in New York (Durvalumab, Tremelimumab)
Not yet recruiting
- Nonsmall Cell Lung Cancer
- Durvalumab
- Tremelimumab
-
New York, New YorkColumbia University Irving Medical Center
Apr 29, 2022
Hepatocellular Carcinoma Trial in Toronto, Milan, Pamplona (Tremelimumab)
Not yet recruiting
- Hepatocellular Carcinoma
- Tremelimumab
-
Toronto, Ontario, Canada
- +2 more
Jun 27, 2022
NSCLC, NSCLC Stage IV Trial in Madison (Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy)
Active, not recruiting
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage IV
- Durvalumab
- +2 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Sep 21, 2022
Metastatic Melanoma Trial in Boston (Tremelimumab, MEDI3617)
Active, not recruiting
- Metastatic Melanoma
- Tremelimumab
- MEDI3617
-
Boston, Massachusetts
- +1 more
Mar 22, 2022
Hepatocellular Carcinoma Trial (Livmoniplimab, Budigalimab, Durvalumab)
Not yet recruiting
- Hepatocellular Carcinoma
- Livmoniplimab
- +5 more
- (no location specified)
Oct 26, 2023
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial
Active, not recruiting
- Fallopian Tube Endometrioid Tumor
- +13 more
- Olaparib
- Tremelimumab
-
Orange, California
- +19 more
Jan 10, 2023
Mesothelioma Trial in Houston (MEDI4736, Tremelimumab, no other name)
Advanced Hepatocellular Carcinoma Trial in Worldwide (Durvalumab, Tremelimumab)
Not yet recruiting
- Advanced Hepatocellular Carcinoma
- Durvalumab
- Tremelimumab
-
La Jolla, California
- +46 more
May 22, 2023